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To gain further insight into the ability of subunit vaccines to protect monkeys from experimental infection
with simian immunodeficiency virus (SIV), two groups of cynomolgus macaques were immunized with either
recombinant SIVmac32H-derived envelope glycoproteins (Env) incorporated into immune-stimulating com-
plexes (iscoms) (group A) or with these SIV Env iscoms in combination with p27gag iscoms and three Nef
lipopeptides (group B). Four monkeys immunized with recombinant feline immunodeficiency virus Env iscoms
served as controls (group C). Animals were immunized intramuscularly at weeks 0, 4, 10, and 16. Two weeks
after the last immunization, monkeys were challenged intravenously with 50 monkey 50% infectious doses of
virus derived from the J5 molecular clone of SIVmac32H propagated in monkey peripheral blood mononuclear
cells. High titers of SIV-neutralizing antibodies were induced in the monkeys of groups A and B. In addition,
p27gag-specific antibodies were detected in the monkeys of group B. Vaccine-induced cytotoxic-T-lymphocyte
precursors against Env, Gag, and Nef were detected on the day of challenge in the monkeys of group B.
Env-specific cytotoxic-T-lymphocyte precursors were detected in one monkey from group A. In spite of the
observed antibody and T-cell responses, none of the monkeys was protected from experimental infection. In
addition, longitudinal determination of cell-associated virus loads at weeks 2, 4, 6, 9, and 12 postchallenge
revealed no significant differences between vaccinated and control monkeys. These findings illustrate the need
to clarify the roles of the different arms of the immune system in conferring protection against primate
lentivirus infections.
Simian immunodeficiency virus (SIV) has a genomic orga-
nization similar to that of human immunodeficiency virus
(HIV) and can induce a disease in certain macaques similar to
human AIDS. Therefore, SIV infection of macaques is widely
used as a model for HIV vaccine research. Previous observa-
tions have provided evidence that whole inactivated SIV vac-
cines can induce protective immunity in macaques (10, 13, 18,
29, 30, 40, 41), although in some of these studies the immune
responses against cellular components of the vaccine proved to
be at the basis of the observed protection (3, 12, 53). Immu-
nization of rhesus macaques with live attenuated SIV has pro-
vided further evidence that the induction of protective im-
munity may be achieved by vaccination (16, 35). However,
concerns about the overall safety of this approach may limit its
potential for the development of HIV type 1 (HIV-1) vaccines.
Subunit vaccines have been proposed as a safe alternative to
inactivated or live attenuated virus vaccines, with the advan-
tage that only antigens relevant for the induction of protective
immunity may be included. In this respect, much attention has
been paid to the envelope glycoprotein (Env) as the major
target of virus-neutralizing (VN) antibodies. Furthermore, Env
has been shown to be recognized by cytotoxic T lymphocytes
(CTL) in both HIV-infected humans and SIV-infected ma-
caques (59). A role for CTL in controlling virus replication has
been suggested from the observation that the clearance of
viremia during primary infection is coincident with the emer-
gence of HIV-1-specific CTL and prior to the development of
detectable VN antibodies (34). Immunization of cynomolgus
macaques with live vaccinia virus expressing Env and a subse-
quent booster injection with recombinant Env did confer pro-
tection against homologous challenge with SIVmne (25). How-
ever, similar immunization protocols did not induce protection
against SIVmac infection (22, 51), although decreased virus
loads were observed in some studies (1, 27).
The relatively conserved Gag protein is another candidate
for inclusion in SIV subunit vaccines. Gag is known to be a
major target for CTL responses in both HIV-1 and SIV infec-
tions (31, 59), in which Gag-specific CTL are believed to play
a role in delaying the onset of disease (9).
Regulatory proteins expressed early in viral replication are
also interesting components of candidate SIV subunit vaccines,
since CTL directed against these proteins may kill infected
cells before the expression of structural proteins and before the
release of infectious virus particles. In this respect, Nef appears
to be of particular interest, since it is abundantly expressed
early in infection and is able to induce CTL responses in both
humans and macaques (14, 15, 58). In HIV-1-infected individ-
uals, several CTL epitopes have been identified in the central
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region of Nef and shown to be recognized in the context of a
broad range of major histocompatibility complex (MHC) hap-
lotypes (14, 15). In SIV-infected macaques, three Nef peptides,
with a sequence highly homologous to that of the central re-
gion of the HIV-1 Nef protein, have been shown to contain
CTL epitopes (7).
The system used for delivery of the selected antigens may
play a crucial role in the generation of adequate B- and T-cell
responses. Particular attention should be given to the induction
of MHC class I-restricted CD81 CTL, because it requires
antigen processing via the endogenous route, which is usually
not accomplished by nonreplicating antigen presentation
forms (for a review, see reference 37). However, proteins in-
corporated into immune-stimulating complexes (iscoms), as
well as peptides bound to a lipid tail, have been shown to
induce CD81 MHC class I-restricted CTL in vitro and in vivo
(6, 17, 36, 39, 50, 55, 57). Interestingly, previous studies have
suggested that gp120-enriched SIVmac32H iscoms are effec-
tive in inducing protection against challenge with cell-associ-
ated SIV (19, 23, 42). Furthermore, HIV-2 iscoms have been
shown to induce long-lasting protective immunity against chal-
lenge with cell-free HIV-2 (43).
In this study, two groups of monkeys were immunized with
either recombinant SIV Env incorporated into iscoms (group
A) or with SIV Env iscoms combined with p27gag iscoms and
three Nef lipopeptides containing the CTL epitopes previously
identified in the central region of Nef (amino acids 108 to 123,
155 to 169, and 164 to 178) (7) (group B). Despite the induc-
tion of VN antibody responses and CTL responses against Env,
Gag, and Nef, none of the monkeys proved to be protected
against intravenous challenge with the J5 molecular clone of
SIVmac32H.
MATERIALS AND METHODS
Formulation of vaccine preparations. (i) Preparation of SIV Env iscoms. Two
Env glycoproteins, referred to as 8672-m and 8789-m, were produced and incor-
porated into iscoms as previously described (26). Briefly, peripheral blood mono-
nuclear cells (PBMC) were derived from two rhesus macaques shortly after
infection either with the 32H isolate of SIVmac251 (November 1988 pool)
(macaque 8789) or with the same virus after it had undergone an 11-month in
vivo passage (macaque 8672) (19). Two SIV Env genes were amplified from
PBMC by PCR, and the putative primary and secondary cleavage sites were
mutated by site-directed mutagenesis. These constructs were cloned in plasmid
pSC65 (kindly provided by B. Moss, Bethesda, Md.) under the control of a
synthetic early-late promoter. Recombinant vaccinia viruses (rVVs) were made
by homologous recombination with vaccinia virus (WR strain). rVVs were used
to infect baby hamster kidney cells. Twenty hours after infection, cells were
harvested, and the rVV was inactivated by paraformaldehyde (PFA) fixation.
Subsequently, the Env glycoprotein was solubilized from the cell membrane by
using Rosenbuch-Tenside (Bachem, Bubendorf, Switzerland), purified by lentil-
lectin chromatography, and eventually incorporated into iscoms. The Env pro-
tein of feline immunodeficiency virus (FIV) strain AM19 (45) was produced and
incorporated into iscoms following the same procedure.
(ii) SIV Gag iscoms. The C-terminal part of p17 and p27 of the SIVmac251 gag
gene was excised from plasmid pKA27 (kindly provided by N. Almond and P.
Kitchin through the Medical Research Council) and cloned into the EcoRI and
Xba sites of plasmid pMALc (New England Biolabs, Inc., Beverly, Mass.). As
only hydrophobic proteins incorporate efficiently into iscoms, a sequence con-
taining 29 amino acids of the hydrophobic part of the transmembrane sequence
of HIV clone 320 (2) (amino acids 683 to 711 [WAGLWNWFSITNWLWYIKI
FIMIVGGLVG]) was amplified by PCR and cloned into the C terminus of the
p27gag gene. The resulting plasmid, pMALc-Gagp27, expresses in Escherichia coli
a fusion product of maltose-binding protein which is linked to SIV p27gag by a
factor Xa cleavage site. The fusion protein was first released from bacteria by
sonication and subsequently purified from bacterial proteins through affinity
chromatography by allowing its maltose-binding protein part to bind to an amy-
lose column. The p27gag protein was released from the column by incubation with
12.5 mg of factor Xa (New England Biolabs) per ml in Xa buffer (20 mM
Tris-HCl [pH 7.4], 100 mMNaCl, 2 mMMgCl2) containing 0.25%MEGA-10, 10
mg of cholesterol per ml, 10 mg of phosphatidylethanolamine per ml, and 2 mg
each of the of protease inhibitors aprotinin and leupeptin per ml. The p27gag
protein was finally collected and incorporated into iscoms by a procedure similar
to that described for the preparation of SIV Env iscoms. The amount of p27gag
present in each iscom preparation was quantified by a commercial antigen cap-
ture enzyme-linked immunosorbent assay (ELISA) (Vironostika, HIV Antigen
Microelisa system; Organon Teknika B.V., Boxtel, The Netherlands) according
to the procedure recommended by the manufacturer. Recombinant p27gag (kind-
ly provided by I. Jones, Oxford, United Kingdom) was used as a standard protein
for quantification.
(iii) Nef lipopeptides. Three Nef lipopeptides were constructed according to
sequences previously found to contain CTL epitopes in SIVmac-infected ma-
caques (7). The following Nef peptide sequences were based on the J5 molecular
clone of SIVmac32H (47): peptide 1 (amino acids 108 to 123), LRTMSYK
LAVDMSHFI; peptide 2 (amino acids 155 to 169), DWQDYTSGPGIRYPK;
peptide 3 (amino acids 164 to 178), GIRYPKTFGWLWKLV. These peptides
were synthesized by standard Fmoc solid-phase methods (20), starting with Rink
amide resin. The N-terminal lysine was coupled as Fmoc-Lys(Fmoc). After Fmoc
deprotection, the N-terminal and the side chain amino group of lysine were
palmitoylated with palmitic anhydride. Two serine residues were introduced
between the N-terminal lysine and the Nef peptide sequence.
Animals and immunization protocol (see Table 1). This study included twelve
colony-bred juvenile cynomolgus macaques (Macaca fascicularis) between 1.5
and 3.5 years old and weighing from 1.4 to 2.9 kg at the beginning of the study.
All monkeys were seronegative for SIV, type D retrovirus, and simian T-lym-
photropic virus. Macaques were allocated to three groups of four monkeys each,
including two male and two female monkeys and different MHC haplotypes.
Animals were immunized intramuscularly at weeks 0, 4, 10, and 16 with either 20
mg of SIV Env iscoms (8672-m Env and 8789-m Env at 10 mg each) (group A)
or with 20 mg of SIV Env iscoms and 10 mg of p27gag iscoms in combination with
the three Nef lipopeptides at 1 mg each (group B). Four monkeys vaccinated with
recombinant FIV Env iscoms served as controls (group C).
SIV challenge. Two weeks after the fourth immunization, monkeys were in-
fected intravenously with 50 monkey 50% infectious doses (MID50) of the cell-
free March 1992 challenge stock (J5M) of SIVmac32H (pJ5), a pathogenic
molecular clone derived from SIVmac32H (November 1988 pool) (47). The
challenge stock derived from this molecular clone had been propagated in rhesus
macaque PBMC and titrated in vivo by intravenous inoculation of rhesus ma-
caques (47). One monkey (K2 [group A]) died during recovery from anesthesia
on the day of challenge.
PBMC isolation. Heparinized blood samples were collected at two-, three-, or
four-week intervals. PBMC were isolated by density gradient separation with a
68:32 (vol/vol) solution composed of 6% dextran (Sigma, St. Louis, Mo.) in
distilled water and 32.8% sodium metrizoate (Nycomed, Oslo, Norway). Plasma
samples were cryopreserved until used. PBMC were used immediately or stored
at 21358C until used.
Quantification of SIV Env-specific serum antibodies by ELISA. Ninety-six-
well plates (Costar, Cambridge, Mass.) coated with concanavalin A (Pharmacia
LKB, Uppsala, Sweden) were incubated with 50 ml of 100-ng/ml lentil-lectin-
purified Env derived from SIVmac32H-infected C8166 cells (19) in phosphate-
buffered saline (PBS) containing 1% Triton X-100. Virus-derived SIVmac32H
was used as immobilized antigen to confirm that the Env-specific antibodies
detected after immunization with vaccinia virus-produced Env glycoprotein rec-
ognized the native protein. Quantification of SIV Env was performed as previ-
ously described (16). Uninfected C8166 cells were used as the negative control.
After 16 h of incubation at room temperature (RT), wells were blocked with PBS
containing 0.1% Tween 20 and 1% bovine serum albumin (PTB) supplemented
with 10% fetal calf serum (FCS) and 0.5% nonfat dry milk. Subsequently, plates
were incubated for 2 h at RT with 50 ml of twofold dilutions of plasma in PTB
containing 4% FCS. After being washed, bound antibody was detected by using
a biotin-conjugated goat anti-human immunoglobulin preparation (Amersham)
and subsequently incubated with horseradish peroxidase-conjugated streptavidin
(Amersham). For substrate reactions, 3,39,5,59-tetramethyl-benzidine was used
(5). Endpoint titers were calculated by using a cutoff value three times above the
respective dilution of the preimmune serum at an optical density at 450 nm.
One-way analysis of variance (Minitab, Inc., State College, Pa.) was used to
compare antibody titers between groups. The level of significance was P , 0.05.
Quantification of SIV Gag-specific serum antibodies by inhibition ELISA.
Gag-specific antibody titers were measured in inhibition ELISAs with biotiny-
lated polyclonal antiserum from an SIVmac-infected monkey. Ninety-six-well
plates (Costar) were coated with 100 ml of a 1:200 dilution in PBS of sonicated
bacterial culture of pMALc-Gagp27 containing about 10 mg of p27gag per ml.
After incubation at RT for 16 h, wells were incubated for 30 min with PTB
containing 10% FCS and then for 60 min at RT with 100 ml of twofold dilutions
of monkey plasma. Fifty microliters was discarded from each well before 50 ml of
biotinylated polyclonal serum in PTB containing 4% FCS was added. This poly-
clonal serum was derived from an SIVmacBK28-infected rhesus macaque (kindly
provided by J. Heeney, TNO, Rijswijk, The Netherlands) and was shown to have
a high titer of Gag-specific antibodies by immunoblotting. It was diluted to give
an absorbance at an optical density at 450 nm equal to 60% of the maximum
absorbance in a direct SIV ELISA. After incubation for 2 h at RT, wells were
washed and incubated with horseradish peroxidase-conjugated streptavidin. For
substrate reactions, 3,39,5,59-tetramethyl-benzidine was used (5). Inhibition titers
were defined as the dilutions of monkey plasma inhibiting 50% of the absorbance
at an optical density at 450 nm without the addition of plasma.
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SIV neutralization assay. The SIV neutralization assay used in these experi-
ments was performed as previously described with SIVmac32H (19). Briefly, 10
ml of serial dilutions of heat-inactivated sera were incubated in four replicate
wells with 10 ml of SIVmac32H diluted to give 10 infectious particles per 10 ml.
After a 30-min incubation at 378C, 200 ml of medium containing 2 3 103 C8166
cells was added to each well. Plates were incubated for 7 days at 378C, after which
the cells from each well were transferred to poly-L-lysine-coated flat-bottom
microtiter plates, fixed in methanol, and examined for the presence of SIVmac-
infected cells by an SIV-specific immunoperoxidase assay. Wells containing no
infected cells were scored as positive, and the number of positive wells was used
to determine the 50% neutralizing dose endpoint for the relative serum. Each
time point was tested twice. The differences in titers among the different groups
at each time point were evaluated by Student’s t test. The threshold of signifi-
cance was P , 0.05.
Determination of frequencies for CTL precursors (CTLp). (i) Preparation of
antigen-presenting cells. Lymphoblastoid B-cell lines (B-LCL) were established
by the incubation of PBMC with supernatant from the S594 cell line producing
herpesvirus papio (44) (kindly provided by R. Bontrop, Rijswijk, The Nether-
lands). Autologous B-LCL were infected for 18 h with rVV expressing either Env
(v8672-m and v8789-m) (26), p55gag (SIVmac32H) (kindly provided by A. Mc-
Michel, Oxford, United Kingdom), or Nef (SIVmac32H clone pJ5) (47a) at a
multiplicity of infection of 10 and then fixed in 1.5% PFA.
(ii) Limiting-dilution microcultures. Cryopreserved PBMC collected on the
day of challenge and at week 9 or 12 postchallenge were thawed and seeded in
parallel in serial dilutions ranging from 43 104 to 13 103 in RPMI 1640 (Gibco,
Gaithersburg, Md.) containing 100 IU of penicillin per ml, 100 mg of strepto-
mycin per ml, 2 mM L-glutamine, and 2 3 1025 M b-mercaptoethanol (referred
to as complete medium) supplemented with 10% heat-inactivated fetal bovine
serum (Hyclone Laboratories, Logan, Utah) (referred to as R-10). Cultures were
set up in 24 replicate wells of 96-well round-bottom plates in a final volume of
100 ml per well. Autologous irradiated (2,500 rads) feeder PBMC were added at
104 per well. Responder cells were stimulated on days 0 and 7 of culture with
autologous rVV-infected B-LCL expressing the appropriate SIV protein at 104
per well. Recombinant interleukin-2 at 10 U/ml was added to microcultures on
days 3, 7, and 10. On day 14, cells from each well were resuspended and two 70-ml
aliquots were screened for cytotoxicity in split-well CTL assays with either rVV
expressing one of the SIV proteins or control wild-type vaccinia viruses (Copen-
hagen strain).
The phenotype of the expanded cell population was assessed on day 15 of
culture by flow cytometry (fluorescence-activated cell sorter [FACS] analysis)
with fluorescein isothiocyanate-conjugated anti-CD4 (Okt4; Ortho Diagnostics,
Raritan, N.J.) and phycoerythrin-conjugated anti-CD8 (Leu 2a; Becton Dickin-
son, Etten-Leur, The Netherlands).
(iii) Cytotoxicity assay. Cytotoxicity was measured in standard 5-h sodium
chromate (51Cr) release assays. Autologous B-LCL infected for 16 h at a mul-
tiplicity of infection of 10 with either rVV expressing one of the SIV proteins or
control wild-type vaccinia viruses (Copenhagen strain) were used as target cells.
These were labelled for 1 h with 100 mCi of 51Cr at 378C in 5% CO2, washed
three times in complete medium, resuspended in R-10 at 105/ml, and added to
effector cells in 50 ml (5,000 cells per well) in 96-well round-bottom plates
(Costar). After a 5-h incubation at 378C in 5% CO2, supernatants were harvested
with a Skatron harvester (Skatron, Oslo, Norway), and the release of 51Cr was
measured in a gamma counter. Maximum 51Cr release was determined by de-
tergent (5% Triton X-100) lysis of target cells. Spontaneous release was deter-
mined by the incubation of target cells in R-10 alone. Maximum 51Cr release and
spontaneous release were set up in 18 replicate wells. Spontaneous release was
,25% of maximum 51Cr release in all assays.
(iv) Calculation of CTLp frequencies. Individual wells were considered posi-
tive when the experimental release of specific targets but control targets ex-
ceeded spontaneous release by 3 standard deviations. CTLp frequencies were
estimated by the method described by Strijbosch et al. (54). Frequencies were
normalized to the number of CTLp per 106 plated cells.
Quantification of cell-associated virus load. Serial fivefold dilutions of freshly
isolated PBMC in R-10 ranging from 1 3 106 to 1.6 3 103 were seeded in
duplicate wells in the presence of 3 mg of concanavalin A per ml. PBMC were
cocultured with the human T-cell line C8166 at 105 cells per ml. Recombinant
interleukin-2 was added on day 3 at 10 U/ml. Cells were cultured for 6 weeks at
378C in a humidified 5% CO2 incubator. Cultures were refreshed twice a week.
Supernatants were assayed regularly for p27gag by antigen capture ELISA (Or-
ganon Teknika). The number of infected cells was calculated from the highest
positive dilution and expressed as the number of infected cells per 106 PBMC.
The differences in the mean values of virus load among the different groups at
each time point were evaluated by Student’s t test. The threshold of significance
was P , 0.05.
RESULTS
Antibody responses induced by the candidate SIV subunit
vaccines. (i) SIV Env-specific serum antibodies.Monkeys were
immunized intramuscularly with the different vaccine prepara-
tions at weeks 0, 4, 10, and 16 as outlined in Table 1. The first
immunization induced Env-specific antibodies in three mon-
keys from group A and two monkeys from group B (Fig. 1A).
The responses in all monkeys increased after the second and
third immunizations but declined rapidly after each booster
injection. After the fourth immunization, antibody titers re-
turned to approximately the same levels as those reached after
the third immunization, that is, at levels similar to those found
after experimental infection. Env-specific antibody titers did
not differ significantly between monkeys from groups A and B.
No SIV Env-specific antibodies were found in the monkeys
from control group C before challenge.
(ii) SIV Gag-specific serum antibodies. p27gag-specific anti-
body levels were measured in two monkeys from group B after
the first immunization and in all monkeys from group B after
the second immunization (Fig. 1B). Titers increased after the
second and third immunizations but declined rapidly after each
booster injection. After the fourth immunization, antibody ti-
ters reached levels similar to those measured after the third
immunization. No p27gag-specific serum antibodies were found
before challenge in monkeys from groups A and C.
(iii) VN serum antibodies. All monkeys from groups A and
B developed VN antibodies to SIVmac32H upon immuniza-
tion (Fig. 1C). These VN antibody titers were similar to or
exceeded those observed after experimental SIVmac infection.
VN antibody titers did not differ significantly between monkeys
from groups A and B. In monkeys from control group C, no
VN antibodies were found before challenge.
CTLp frequencies on the day of challenge. The abilities of
candidate SIV subunit vaccines to induce SIV-specific CTLp
were studied by limiting-dilution analyses of PBMC collected
on the day of challenge (Table 2). The CTLp frequencies of
replicate experiments fell consistently within the same range,
with largely overlapping 95% confidence intervals. More spe-
cifically, the coefficient of variation for 12 replicate experi-
ments of both Env- and Gag-specific CTL responses showed a
mean of 8.1%. Relatively high levels of CTLp specific for Env,
Gag, and Nef were detected in PBMC from group B monkeys
K80 and K83, ranging from 7 to 105/106 PBMC. The highest
CTLp frequencies were found for Env (105 and 25/106 PBMC,
respectively). These responses were clearly vaccine induced
since no specific CTLp were detected in PBMC collected from
these monkeys before immunization. The other two monkeys
in group B, K77 and K88, showed CTLp against two of the
three proteins (K77, Gag- and Nef-specific CTLp; macaque
K88, Env- and Gag-specific CTLp), albeit at lower levels (2 to
15/106 PBMC). In the monkeys from group A, only macaque
TABLE 1. Immunization schedule for cynomolgus macaques
Group Monkeys Immunogensa mg/dose
A 769, K70, K81, K2 SIV Env iscom 8672-m 10
SIV Env iscom 8789-m 10
B K77, K80, K83, K88 SIV Env iscom 8672-m 10
SIV Env iscom 8789-m 10










C K66, K71, K73, K79 FIV Env iscoms 10
aMonkeys were immunized intramuscularly at weeks 0, 4, 10, and 16 and
challenged intravenously at week 18 with 50 MID50 of the J5 molecular clone of
SIVmac32H.
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769 exhibited low levels of Env-specific CTLp (1/106 PBMC).
To investigate whether the CTL responses found were MHC
restricted, cells expanded by Env-specific stimulation of PBMC
from monkey K80 were tested against autologous and MHC
class I-mismatched rVV Env-infected target cells. Lysis of the
autologous target cells but not of the MHC class I-mismatched
target cells was detected, indicating that the CTL responses
induced were indeed predominantly MHC class I restricted
(data not shown). In addition, with cells from the same mon-
key, FACS analysis was performed on day 15 with cultures
exhibiting Env-specific CTLp activity. The majority of ex-
panded cells proved to be of the CD81 phenotype (CD81,
69%; CD41, 17%).
SIV-specific serum antibodies after challenge. Env-specific
antibody titers decreased during the first 2 weeks after chal-
lenge in the monkeys from groups A and B but showed an
anamnestic response that peaked at week 4 or 6 postchallenge
(Fig. 1A). Env-specific antibodies were also detected in the
monkeys from control group C, starting at week 4 or 6 after
infection and increasing gradually afterwards. In all three
groups of monkeys, Env-specific antibody titers eventually
reached a plateau at about the same level. VN antibody de-
velopment in the monkeys from groups A and B also showed
an anamnestic response (Fig. 1C). In the monkeys from group
C, VN antibodies were induced following infection. With the
exception of monkey K88, in all of the monkeys from group B,
FIG. 1. Pre- and postchallenge SIV-specific antibody responses in group A, B, and C monkeys. (A) SIV Env-specific serum antibodies, as determined by indirect
ELISA with SIVmac32H-derived Env as immobilized antigen. (B) SIV Gag-specific antibodies, as determined by inhibition ELISA. Bacterial p27gag was used as
immobilized antigen. Biotinylated polyclonal serum of an SIVmac-infected monkey was used for inhibition. (C) SIVmac32H VN antibody responses. Serial dilutions
of monkey plasma were incubated with SIVmac32H and added to C8166 cells. The number of negative wells was used to determine the 50% neutralizing dose endpoint
titer for the relative plasma. The weeks of immunizations are indicated by small arrows. The day of challenge is indicated by a large arrow. Group A monkeys (Env
immunized): }, 769; {, K70; 1, K81; 3, K2. Group B monkeys (Env-Gag-Nef immunized): , K77; , K80; , K83; , K88. Group C monkeys (control): E, K66; n,
K71; F, K73; h, K79. Monkey K2 (group A) died during recovery from anesthesia on the day of challenge.





p27gag-specific plasma antibody titers declined 2 weeks after
challenge but showed an anamnestic response that peaked at
week 4 postchallenge (Fig. 1B). p27gag-specific antibody re-
sponses were also induced after challenge in the monkeys from
groups A and C.
SIV-specific CTLp frequencies after challenge. The frequen-
cies of CTLp specific for Env, Gag, and Nef were measured at
week 9 or 12 postchallenge in PBMC from group A and B
monkeys (Table 2). Postchallenge CTLp measurements were
carried out in parallel with those of prechallenge CTLp under
identical culture and assay conditions. In monkey K80 (group
B), the frequencies of Env- and Gag-specific CTLp were sim-
ilar to those detected on the day of challenge, whereas the
frequency of Nef-specific CTLp showed a marked increase. In
monkey K83 (group B), the frequencies of Gag- and Nef-
specific CTLp were similar to those measured on the day of
challenge, whereas the frequency of Env-specific CTLp
showed a slight decrease. Monkey K88 (group B) showed an
increase in both Env- and Gag-specific CTLp after challenge
and the induction of relatively low levels of Nef-specific CTLp.
In monkey K77 (group B), Env-specific CTLp were induced
after challenge. In the same monkey, Gag- and Nef-specific
CTLp were detected, with a marked increase in the latter.
Env-specific CTLp were detected in all of the monkeys from
group A after challenge. In the same group, Gag-specific CTLp
were detected at relatively low (monkeys 769 and K70) or high
(monkey K81) frequencies. No Nef-specific CTLp were dem-
onstrated in any monkey from group A.
Cell-associated virus loads. After challenge with 50 MID50
of the J5 molecular clone of SIVmac32H, all animals became
infected, as illustrated by repeated isolation of SIV from their
PBMC (Fig. 2). SIV was isolated from all monkeys at week 2
postchallenge. Longitudinal evaluation of cell-associated virus
loads showed that the number of SIV-infected cells in circula-
tion fluctuated over time, with a peak at 2 or 4 weeks after
challenge. Furthermore, virus loads differed considerably
within and among the groups. The mean value of virus load for
the monkeys from control group C was consistently higher than
that for the vaccinated groups, with the exception of the values
at week 12. However, the differences in virus loads did not
reach statistical significance.
DISCUSSION
In this paper, we have shown that SIV subunit vaccines
consisting of Env glycoproteins incorporated into iscoms either
FIG. 2. Cell-associated virus loads in the PBMC of SIV-vaccinated (groups A [A] and B [B]) and control (group C [C]) monkeys during a 12-week follow-up period.
Serial fivefold dilutions of PBMC ranging from 106 to 960 for week 2 postchallenge and from 106 to 1,600 for all other time points were incubated with C8166 cells
for 6 weeks. The number of infected cells per 106 PBMC was calculated from the highest dilution that was positive in a p27gag antigen capture ELISA. Group A (Env)
monkeys:n, 769;h33, K70;h/ /, K81. Group B (Env-Gag-Nef) monkeys: , K77;n, K80;h, K83; , K88. Group C (control) monkeys: , K66; ,
K71;h\ \, K73;h, K79.
TABLE 2. Pre- and postchallenge Env-, Gag-, and Nef-specific CTLp frequenciesa
Group Macaque
Frequency (CTLp/106 PBMC)b
Day of challenge Wk 9 or 12 postchallenge
Env Gag Nef Env Gag Nef
A 769 1 (0–3) ND ND 8 (4–12) 2 (0–3) 0
K70 0 ND ND 3 (1–5) 1 (1–2) 0
K81 0 ND ND 13 (8–17) 10 (6–14) 0
B K77 0 2 (0–5) 4 (0–10) 8 (0–16) 5 (0–10) 17 (10–24)
K80 105 (80–130) 10 (5–15) 7 (3–11) 110 (96–151) 15 (9–20) 63 (49–76)
K83 25 (16–34) 13 (4–22) 11 (5–17) 8 (4–12) 11 (6–16) 10 (4–16)
K88 15 (4–26) 3 (0–8) 0 95 (74–116) 19 (7–30) 2 (0–6)
a Effector cells were obtained by specific stimulation with PFA-fixed autologous B-LCL infected with rVV expressing the respective SIV protein in the presence of
recombinant interleukin-2. Split-well 51Cr release assays were performed on day 14 of culture. Specific cytotoxicity was assayed with autologous B-LCL infected with
either rVV expressing the SIV protein under investigation or wild-type control vaccinia virus. Data from limiting-dilution assays were analyzed with maximum likelihood
and minimum chi-square methods.
b Env-, Gag-, and Nef-specific CTLp frequencies were also measured in the PBMC of K80, K83, and K88 (Env only) before immunization, and no CTLp were
detected. The 95% confidence intervals are in parentheses. ND, not done.
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alone or in combination with p27gag iscoms and Nef lipopep-
tides failed to generate protection against intravenous SIVmac
challenge, despite the induction of VN antibodies and CTL
responses.
The two Env glycoproteins used for immunization, 8789-m
and 8672-m, shared 98.6 and 97.0% amino acid sequence ho-
mology, respectively, with the Env protein of the J5 molecular
clone of SIVmac32H used for challenge (26). Because most of
the VN antibodies detected in sera from infected monkeys
recognize conformational epitopes (28), it is considered im-
portant that recombinant Env proteins are presented to the
immune system in a form that most closely resembles the
native conformation. In fact, using a panel of 15 monoclonal
antibodies recognizing both conformational and linear
epitopes, we have recently shown that the antigenicity of the
recombinant Env proteins used in this study is similar to that of
virus-derived Env protein (26). Furthermore, we found here
that the VN antibody titers induced by the two recombinant
Env proteins incorporated into iscoms in group A and B mon-
keys were similar to or exceeded those found after experimen-
tal SIVmac infection.
VN antibodies were measured with the 32H strain of SIV-
mac cultured in C8166 cells. It has previously been shown that
antibodies which neutralize SIVmac32H also efficiently neu-
tralize the J5 molecular clone derived from this virus (11a).
The VN antibody titers on the day of challenge did not show
inverse correlations with the levels of virus load measured after
challenge. This is in agreement with previous studies carried
out with the SIV macaque model, which failed to demonstrate
a correlation between VN antibody titers and resistance to
experimental SIV infection (13, 18, 24, 40). It should be
pointed out, however, that in all of these studies, VN assays
were based on the neutralization of virus propagated in T-cell
lines. There are clear indications that the neutralization of
HIV and FIV propagated in susceptible cell lines is more easily
accomplished than neutralization of virus propagated on pri-
mary lymphocyte cultures (4, 48, 52). In light of these obser-
vations, one may speculate that the biological significance of
the VN antibodies measured in our vaccinated monkeys is
limited. The development of VN assays with monkey PBMC
and non-cell-line-adapted SIV might help to demonstrate bi-
ologically more significant antibodies.
The method we used for the determination of CTLp fre-
quencies was established in studies carried out with HIV-1-
infected individuals (21, 33, 56) as well as SIVmac-infected
monkeys (20a). The frequencies of SIV Env-, Gag-, and Nef-
specific CTLp were measured in parallel assays of PBMC from
the day of challenge and from week 9 or 12 postchallenge.
Replicate experiments showed good reproducibility of CTLp
frequency estimates.
The use of both iscoms and lipopeptides proved to be effec-
tive in inducing SIV-specific CTL responses in the monkeys
from group B. As can be expected for analysis of an outbred
population of monkeys, the frequencies of SIV-specific CTLp
differed considerably among similarly immunized monkeys.
The highest CTLp frequencies were those for the Env protein
and appeared to be similar to those previously observed for
SIVmac251-infected macaques (58). The vaccine-induced
Gag- and Nef-specific CTLp frequencies were lower but com-
parable to those found by Yasutomi et al. in both vaccinated
and SIVmac-infected macaques (60).
To achieve in vitro expansion of SIV-specific CTLp, autol-
ogous B-LCL infected with rVV expressing the respective SIV
proteins and fixed in PFA were used for specific antigen stim-
ulation. This protocol has previously been shown to selectively
expand MHC class I-restricted CD81 CTL against the Gag
protein of HIV-1 (56). The same approach has now also
proved to selectively expand MHC class I-restricted CD81
CTL against SIV antigens (20a). In agreement with previous
findings, the Env-specific cytotoxic response of monkey K80,
which showed the highest frequency after vaccination, ap-
peared to be predominantly directed against autologous tar-
gets but not MHC class I-mismatched targets, suggesting that
the killing was mediated by MHC class I-restricted CTL rather
than by NK cells (46). In addition, in the same monkey the
majority of cells expanded by Env-specific antigen stimulation
showed a CD81 phenotype. To our knowledge, this is the first
demonstration of the induction of CTL responses in primates
with antigens incorporated into iscoms.
In the monkeys from group A (immunized with Env iscoms
alone), only one showed low-level Env-specific CTLp re-
sponses on the day of challenge. However, the ability of these
monkeys to mount a CTL response against the Env protein was
demonstrated by the detection of Env-specific CTLp after
challenge. Although the number of monkeys in group A is too
small to allow drawing any further conclusions, it may be spec-
ulated that in the monkeys from group B, simultaneous immu-
nization with different SIV antigens may have improved the
induction of Env-specific CTL, for example, by a mechanism of
increased virus-specific T-helper-cell activity (49).
After challenge, an increase in SIV-specific CTLp was ob-
served in some cases. This variability is in line with observa-
tions that the frequencies and kinetics vary considerably
among infected monkeys (20a). This observation, also made
for HIV-1-infected individuals (33), may reflect various de-
grees of homogeneity of CTL populations induced by vaccina-
tion or infection (11, 32, 38).
Upon immunization with the three Nef lipopeptides, Nef-
specific CTLp were found in three of four monkeys. These
monkeys had not been selected on the basis of their MHC
haplotypes. Similarly, Bourgault et al. (6) noted that 6 of 12
unselected macaques showed CTL responses after immuniza-
tion with a set of peptides also derived from the central region
of Nef. This indicates that this region, like the corresponding
region of HIV-1 Nef (14, 15), is recognized by CTL in the
context of a range of different MHC class I haplotypes, stress-
ing its potential for vaccine development purposes.
Nef has previously been shown to be an efficient CTL target
in SIV-infected macaques; 8 of 12 monkeys displayed Nef-
specific CTL responses (58). In our study, a similar number
(four of seven monkeys) was found to display Nef-specific CTL
activity after infection. Interestingly, no Nef-specific CTLp
were detected at 12 weeks postchallenge in the monkeys from
group A, whereas in the monkeys from group B (which had
been immunized with the Nef lipopeptides), Nef-specific CTLp
frequencies were either highly increased (K77 and K80), main-
tained (K83), or induced (K88) following infection. This find-
ing allows speculation of a priming effect exerted by immuni-
zation with the three Nef lipopeptides in the monkeys from
group B.
In SIV-infected monkeys, the presence of SIV-specific CTL
has been shown to correlate with a better clinical outcome of
infection, suggesting that vaccine-induced CTL contribute to
protective immunity (8, 58). In one of our previous vaccine
studies, four of eight monkeys appeared to be protected from
challenge with cell-associated SIVmac (19). MHC class I-as-
sociated protection was observed; all of the animals protected
against cell-associated virus challenge shared the MHC class I
allele Mamu-A26 with the monkey cells used for challenge
(24). This suggested that virus-specific CTL directly recognized
the SIV-infected donor cells in an MHC-restricted manner. In
this light, it is interesting that SIV-vaccinated Mamu-A26-pos-
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itive monkeys, like the monkeys in this study, were not pro-
tected from challenge with cell-free, monkey-cell-grown SIV-
mac. In agreement with our observations, Yasutomi et al. have
recently shown that a vaccine-elicited CTL response specific
for a single viral epitope does not protect macaques from
SIVmne challenge (60). They proposed the presence of CTL
with only one specificity and the absence of VN antibodies as
an explanation for the lack of protection. In this study, how-
ever, vaccine-induced VN antibodies and CTLp specific for
one regulatory and two structural proteins apparently did not
protect monkeys from experimental SIVmac infection. If CTL
responses do play a significant role in mediating protection
against SIV infection, it may be argued that CTLp frequencies
should reach very high levels to exert a protective effect. On
the other hand, CTL responses may have a beneficial effect on
the course of infection despite their inability to clear SIV
infection. In fact, although all monkeys were still clinically
healthy 1 year after challenge, preliminary data suggest that
the absence of CTLp early in infection may indeed correlate
with a more rapid decrease in total CD4 counts later in infec-
tion.
An evaluation of the kinetics of cell-associated virus loads
showed no significant differences among the respective groups
of monkeys during a 12-week follow-up period. Indeed, we
found that the virus loads fluctuated considerably over time. In
fact, a higher mean virus load was measured in the PBMC of
control monkeys than in those of the monkeys from groups A
and B, especially at week 6 postchallenge. However, the op-
posite was true at week 12 postchallenge. This indicates that
kinetic studies rather than measurements at one time point are
required when virus loads are considered as a parameter for
protection.
Taken together, our results show that candidate SIV subunit
vaccines based on iscoms and lipopeptides efficiently induced
specific VN antibodies and CTLp. However, the presence of
VN antibodies and CTLp specific for multiple SIV proteins on
the day of challenge proved to be insufficient to protect mon-
keys from intravenous SIVmac challenge. These findings indi-
cate that the type of immunity needed to prevent infection may
be quite different from that thought to control persistent in-
fection with primate lentiviruses.
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